Effect of N-acetyl cysteine on Parkinson’s disease

Effect of N-acetyl cysteine as an adjuvant therapy on Symptoms and Progression of Parkinson’s disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181006041247N1

Enrollment

Registered

2021-01-03

Start date

2019-04-09

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease. Parkinson's disease

Interventions

Intervention 1: Intervention group: Parkinson's disease patients receive N-acetylcysteine for one year. two times per day, every time 600 mg. The medicine is consumed after breakfast and after dinner

Eligibility

Sex/Gender

All

Age

35 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patient's informed consent No brain surgery in the patient's post medical history

Exclusion criteria

Exclusion criteria: having brain surgery within a year before starting the treatment period

Design outcomes

Primary

Measure	Time frame
The quality of the patient's movement skills and intellectual function. Timepoint: Before and after the invention (one year). Method of measurement: Filling the Unified Parkinson's Disease Rating Scale (UPDRS) questionnaire according to the patient's interview and examining.;Changes in dopaminergic areas within the patient's brain. Timepoint: Before and after the invention (one year). Method of measurement: Technetium-99m-Trodat-1 single-photon emission computerized tomography (SPECT).	—

Measure

Time frame

The quality of the patient's movement skills and intellectual function. Timepoint: Before and after the invention (one year). Method of measurement: Filling the Unified Parkinson's Disease Rating Scale (UPDRS) questionnaire according to the patient's interview and examining.;Changes in dopaminergic areas within the patient's brain. Timepoint: Before and after the invention (one year). Method of measurement: Technetium-99m-Trodat-1 single-photon emission computerized tomography (SPECT).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArman Rahimmi

Sanandaj University of Medical Sciences

armanrahimmi@gmail.com+98 87 3316 2929

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026